Research Article

In Vitro Antibacterial Experiments of Qixingjian Decoction and Its Synergistic Interaction with Oxacillin against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus

Siyuan Lv, Tingxuan Huang, Ying Lin, Xingwei Yao, Huiyong Yu, Guoxing Liu, Yue Zhang, Tong Liu, Huan Liang, and Chengxiang Wang

1 Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
2 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China

Correspondence should be addressed to Chengxiang Wang; wangchegnxiang2001@163.com

Received 14 December 2021; Accepted 27 January 2022; Published 16 February 2022

Academic Editor: Jorddy Neves Cruz

Copyright © 2022 Siyuan Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. With the widespread use and abuse of antimicrobial drugs, the problem of bacterial resistance is becoming increasingly prominent. The clinical detection rate of drug-resistant bacteria is increasing year by year, so there is an urgent need to develop new antimicrobial drugs. Qixingjian Decoction (QXJT) is a formula commonly used in Chinese medicine for the treatment of sepsis caused by acute purulent infections of the face, hands, and feet. There are many compounds with antimicrobial effects that are available, but little is known about their mode of action. In this study, we mainly evaluated the antimicrobial activity of QXJT and explored its synergistic interaction with oxacillin (OX) and the mechanism of its antimicrobial activity.

Methods. The antimicrobial activity of QXJTagainst methicillin-resistant Staphylococcus aureus (MRSA) was determined by the microdilution method, the broth macrodilution method, and the time-kill curve method. The main compounds in QXJT were analyzed by ultra-performance liquid chromatography. The synergistic interaction of QXJT and oxacillin (OX) was determined by checkerboard assay, and the antimicrobial mechanism of QXJT, OX, and QXJT + OX was evaluated by transmission electron microscopy (TEM) technique. The expression of MRSA superantigen virulence factors (sea, seb, and tst), and drug resistance gene (mecA) was detected to provide a new strategy for new antibiotic drugs. Results. QXJT exhibited antimicrobial activity against both clinical isolates of MRSA, MICs ranging from 18.75 to 37.5 mg/mL. Active substances such as Scutellarein, Scutellarin, Apigenin, and Wogonin 7-O-glucuronide were detected in the phytochemical analysis that may be associated with the antimicrobial activity of QXJT. The synergistic effect of QXJT and OX was determined by checkerboard assay (FICI = 0.5), and TEM images showed that QXJT could cause the disruption of MRSA cell wall, and QXJT + OX could produce greater disruption of MRSA cell wall, elucidating the synergistic effect of the two together on cell wall disruption by microscopic mechanisms. Our study shows that the combination of QXJT and OX can inhibit the expression of MRSA virulence factor, reduce the virulence of MRSA, and have no significant effect on the expression of MRSA resistance gene mecA. Conclusion. The results of this study provide scientific experimental data for the traditional application of QXJT and initially explore the mechanism of action of QXJT combined with OX.

1. Introduction

Since ancient times, nature plants have been used in medicine and are still used today [1]. Nature plants have been the most important source of antibiotic lead compounds and they also can be used to respond to the growing antibiotic resistance crisis [2]. The major strength of nature plants lies in their various antibacterial modes of action and the proven clinical effectiveness of plant extracts from which they are isolated [3].

Traditional Chinese medicine (TCM) has been practiced for thousands of years, and many of the herbal drugs and decoctions, particularly classical TCM decoctions, are still being used in modern Chinese medicine [4]. Qixingjian decoction (QXJT) has been clinically used in traditional Chinese medicine for more than 700 years [5, 6]. It was first
Evidence-Based Complementary and Alternative Medicine

2. Materials and Methods

2.1. Drugs. QXJT was purchased from Beijing TRT Group (Beijing, China) and identified by Professor Wang Chengxiang of Beijing University of Chinese Medicine. QXJT consists of Wild Chrysanthemum (9 g), Fructus Xanthii (9 g), Herba Siegesbeckiae (9 g), Scutellaria Barbata (9 g), Herba Violae (9 g), Ephedra (3 g), and Paris Polyphylla (6 g). The above herbs were refluxed and extracted with a 10-fold quantity of deionized water for 1 h in a 1 L electric heating jacket and then filtered through 8 layers of gauze. The drug residue was further refluxed and extracted with an 8-fold quantity of deionized water for 1 h and then filtered through 8 layers of gauze. The two filtrates were combined and concentrated to 300 mg/mL by rotary evaporator and stored in a refrigerator at −60°C. Before the in vitro experiment, the product was sterilized in an autoclave at 0.1 MPa and refrigerated at −60°C for 15 min. The quality of the herbs was consistent with the standards of Chinese Pharmacopoeia (2020). The chemical fingerprint of QXJT (ultraperformance liquid chromatography-Q Extract hybrid quadrupole orbitrap high-resolution accurate mass spectrometry [UHPLC-Q-orbitrap HRMS]) was analyzed (Figure 1) (Table 1), and the detailed method of UHPLC-Q-orbitrap HRMS is provided in the supplemental data.

Oxacillin (product name: Oxacillin sodium capsule, serial number: 210503, Sichuan Pharmaceutical Preparation Co., LTD.) was purchased from the Third Affiliated Hospital of BUCM and configured to a concentration of 64 mg/ml using phosphate-buffered saline (PBS) as a positive drug control. Before the experiment, the positive drug was used as 0.22 μl membrane for bacteria removal.

2.2. Bacterial Strains and Culture Conditions. The tested MRSA strains (2007118 and 2008043) were kindly provided by Prof. Lin Ying isolated from clinical patients (Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China). All bacterial strains were cultured according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [14].

2.3. Growth Curve of MRSA by Microplate Reader Measure. The growth curve of MRSA was performed according to Xu et al. [15] with some modifications. The optimum detection wavelength of MRSA absorbance was selected at 630 nm. 50 ml sterile centrifuge tubes were taken; we added 1 ml of bacterial solution (bacterial solution concentration 5 × 10^5 CFU/mL) and incubated it for 24 h at 37°C and 200 r/min in a shaker. The bacterial growth was monitored every two hours until 24 h. The OD 630 nm value was analyzed by statistical software. Then growth curve of MRSA was plotted to determine the optimal culture time in an in vitro bacteriostatic test.

2.4. Evaluation of Minimum Inhibitory Concentrations (MICs). For the determination of MICs, the broth macrodilution method and the broth microdilution method were approved by Clinical and Laboratory Standard Institute (CLSI) with some modifications [14]. According to the preexperiment results, the wells around the 96-well plate were left empty because evaporation would affect optical density (OD) value, and the control (QXJT) group was added to exclude the effect of the excessive dark color of QXJT. QXJT was diluted with twofold serial dilutions to a final concentration of 2.34–75 mg/mL. Oxacillin (OX) was diluted with twofold serial dilutions to a final concentration of 0.125–8 mg/mL. Bacteria were collected, washed, and diluted with phosphate-buffered saline (PBS) to 5 × 10^6 CFU/mL. MIC analysis was performed in microtitration plates with 100 μl QXJT or OX, 10 μl bacterial suspension, and 100 μl Mueller–Hinton broth followed by incubation at 37°C for 24 h (Figure 2(a)). Each experiment was performed three times. MIC was defined as the lowest concentration, which prevented visible (naked eye) bacterial growth.

For broth macrodilution method test, QXJT was diluted with twofold serial dilutions to a final concentration of 2.34–75 mg/mL. Tubes were inoculated with the test microbes. Tubes were incubated using a shaker incubator at 37°C for 24 h.
Figure 1: Total ion chromatography (TIC) on positive (a) and negative (b) and extraction ion chromatography (EIC, (c)–(f)).
2.5. A Time-Kill Assay. A time-kill assay was performed according to CLSI guidelines (15). MRSA was cultured overnight and was adjusted to a $5 \times 10^5$ CFU/mL suspension with phosphate-buffered saline (PBS) (pH 7.4). Inocula were treated at 37°C with prescribed concentrations (1/4 MIC–8 MIC) of QXJT and with normal saline as a negative control. The OD630 nm value was monitored every two hours until 24 h and was analyzed by statistical software. Each experiment was performed three times.

2.6. Checkerboard Assay. The checkerboard assay, commonly used for measuring interactions [16], was used to determine synergy between the OX and QXJT. The range of drug concentrations used in the checkerboard assay was the dilution range included the MIC for each drug used in the analysis. The fractional inhibitory concentration (FIC) was derived from the lowest concentrations of the OX and QXJT in combination, permitting no visible growth of the test organisms in the Mueller–Hinton broth after incubation for 24 h at 37°C. The FIC index was calculated as $\text{FICI} = \frac{\text{MIC of combination}}{\text{MIC of alone A}} + \frac{\text{MIC of combination}}{\text{MIC of alone B}}$. Schelz et al. [17] defined synergy as $\text{FICI} \leq 0.5$, additivity as $0.5 < \text{FICI} \leq 1$, indifference as $1 < \text{FICI} \leq 4$, and antagonism as $\text{FICI} > 4$.

2.7. Transmission Electron Microscopy. MRSA was cultured overnight and was adjusted to a $5 \times 10^5$ CFU/mL suspension with phosphate-buffered saline (PBS) (pH 7.4) and then was treated by 1/2 MIC QXJT, 1/2 MIC OX (pre-experiment proved that it is not easy to collect a sufficient amount of Samples by the concentration above 1/2 MIC), incubated at 37°C for 24 h. To collect a sufficient amount of samples, the tubes were centrifuged at 2000 r/min for 6 minutes. Samples were rinsed two times with PBS (operated gently before fixing samples and minimized the number of rinses to avoid damage) and added 2.5% glutaraldehyde to fix at 4°C for 3 hours. Samples were rinsed again with PBS 3 times and were dehydrated with a graded acetone series and embedded in Spurr’s resin. Thin slices were cut with an RMC MT-7000 ultramicrotome (Ventana) and stained with 1% uranyl acetate and Reynold’s lead citrate before being seen on a transmission electron microscope at 80 kV (H-7500; Hitachi).

| No. | RT (min) | Name                          | Formula                  | Ion        | Cal. m/z  | Mea. m/z  | Error (ppm) | MS/MS    |
|-----|----------|-------------------------------|--------------------------|------------|-----------|-----------|-------------|----------|
| 1   | 1.78     | Uridine                       | C₉H₁₂N₂O₆ [M-H]          | 243.0622   | 243.062   | 3.445     | 243.062, 110.0271 |
| 2   | 4.74     | Scutellarin                   | C₂₁H₁₉O₁₂ [M-H]          | 461.0725   | 461.0733  | 4.007     | 461.0733, 285.0403 |
| 3   | 5.886    | Luteolin-7-O-β-D-glucuronide | C₂₁H₁₈O₁₂ [M-H]          | 461.0725   | 461.0731  | 3.574     | 461.0731, 285.0398 |
| 4   | 6.155    | Luteolin                      | C₁₅H₁₀O₆ [M-H]           | 285.0404   | 285.0398  | 1.528     | 175.0409, 151.0047, 133.0307 |
| 5   | 6.41     | Polyphyllin VI                | C₂₉H₂₆O₁₃ [M+H]          | 739.4263   | 739.4256  | 3.091     | 721.4129, 577.2560 |
| 6   | 6.708    | Apigenin 7-O-beta-D-glucuronide | C₂₂H₂₀O₁₁ [M-H]       | 459.0932   | 459.0933  | 2.423     | 459.0933, 268.0372 |
| 7   | 6.85     | Scutellarein                  | C₁₅H₁₀O₆ [M-H]           | 285.0404   | 285.0408  | 5.036     | 285.0408, 255.0243 |
| 8   | 7.007    | Wogonin 7-O-glucuronide       | C₂₂H₂₀O₁₁ [M-H]          | 459.0932   | 459.0923  | 0.244     | 459.0923, 283.0610, 268.0372 |
| 9   | 8.355    | Apigenin                      | C₁₅H₁₀O₅ [M-H]           | 269.0455   | 269.0461  | 6.133     | 225.0551, 151.0555 |

Table 1: Chemical identification.

Figure 2: (a) MRSA2007118 image of blood plate with three streaking method. (b) MRSA2008043 image of blood plate with three streaking methods.
2.8. Quantitative Reverse-Transcription PCR. To compare the effect of 1/2MIC as well as MICs QXJT, OX, and QXJT + OX (derived from the checkerboard dilution method) on the expression of MRSA drug-resistant genes (mecA) as well as superantigen virulence genes (tst, sea, and seb), 1 ml of the above concentrations was added to test tubes, respectively, and 0.1 ml of MRSA bacterial solution and 1 ml of broth were added in each tube and incubated for 24 h. Quantitative reverse-transcription PCR (RT-qPCR) was performed as previously described by Li et al. [18] with some modifications. Total RNA was extracted using a bacterial RNA extraction kit for qRT-PCR according to the manufacturer’s instructions. Total RNA (0.2 μg) was reverse-transcribed into cDNA using EasyScript First-Strand cDNA Synthesis SuperMix (TransGene, Beijing, China). Reactions were performed in triplicate using a Power SYBR®Green PCR Master Mix (Applied Biosystems, Warrington, UK) and the Applied Biosystems 7500 system. The mRNA expression levels of the genes were normalized to the 16S rRNA gene, compared with 0.9% NaCl-treated bacterial, and quantified by the 2−ΔΔCt method. The sequences of the primers are presented in Table 2.

3. Statistical Analysis

All data were representative of the results of at least three independent experiments. For in vitro experiments, the MIC values were presented as number. Data for the growth curve of MRSA and the time-kill assay were presented as the mean ± standard deviation (S.D.). Quantitative reverse-transcription PCR randomized design with three replications was performed. Comparison between two groups with normal distribution and homogeneity of variance was analyzed using the unpaired t-test. A value of p < 0.05 was regarded as statistically significant. All data were analyzed using SPSS 25.0 software (IBM, Armonk, NY, USA) or GraphPad Prism software.

4. Results

4.1. Growth Curve of MRSA by Microplate Reader Measure. After isolation and purification, the clinical strains were identified as MRSA (Figure 2) by Biomeere’s VITEKAMS30 identification system after culture. The growth curves of MRSA strains were plotted in three independent experiments. As shown in Figure 3, within 24 h, OD 630 nm value and MRSA concentration gradually increased as the culturing time increased. MRSA2007118 and MRSA2008043 had little difference. It could be preliminarily judged that the growth rule of MRSA is th following: 0~10 h slow period, 10~14 h logarithmic growth period, 15~18 h stability period (plateau), and >18 h decline period. According to the growth curve of MRSA, the optimal culture time of in vitro bacteriostatic test was determined to be 18~24 h.

4.2. Evaluation of Minimum Inhibitory Concentrations (MICs). QXJT had antimicrobial effects on MRSA. According to Figure 4, the liquid in the MIC well was straightforward and without bacterial growth, which was not different from the control (QXJT). The MICs of QXJT against MRSA2007118 and MRSA2008043 were 18.75 mg/ml and 37.5 mg/ml, respectively. QXJT exhibited significant antimicrobial activity against the tested MRSA. Each experiment was independently repeated three times.

4.3. A Time-Kill Assay. To further verify the inhibitory effect of QXJT on MRSA, a time-kill curve was made by detecting the OD values after treatment of MRSA with different concentrations of QXJT. The data were analyzed as shown in Figure 5. The time-killing curves of the 2 MRSA strains were similar. When MRSA was treated with 1/4 MIC, the OD630 nm value did not decrease significantly after 24 hours, but it served to delay the logarithmic growth period of MRSA. When MRSA was treated with 1/2 MIC, the OD630 nm value after 24 h could be significantly reduced. When the bacteria were treated with concentrations of MIC, 2 MIC, and 4 MIC, the OD630 of MRSA was almost unchanged between 0 and 24 h. These data suggested that QXJT could inhibit MRSA growth with a significant concentration dependence.

4.4. Checkerboard Assay. The MICs of OX against MRSA2007118 and MRSA2008043 were 4 mg/ml and 1 mg/ml, respectively. The synergistic effect of QXJT in conjugation with OX was evident in the FIC indices shown in Table 3. Overall, test microorganisms showed FIC index (>0.5) on the checkerboard assay, which indicates a synergism effect in the combination of QXJT and OX.

4.5. Transmission Electron Microscopy. To further observe the damage of QXJT on bacteria and the synergistic effect of QXJT + OX and explore the possible mechanism of action, we observed MRSA2007118 treated with QXJT, OX, and QXJT + OX at 1/2 MIC by TEM, respectively. Untreated cells are shown in Figures 6(a) and 6(b). Normal MRSA organisms were intact, almost round, with continuous cell walls, well-defined edges, and uniform cytoplasmic distribution. MRSA organisms treated with 1/2 MIC QXJT for 24 h showed deformation of the organism, vacuoles in the cytoplasmic region, slight cytoplasmic consolidation, incomplete cell wall, increased surface projections, severe damage to the organism, and cytoplasmic leakage (Figures 6(c) and 6(d)). After 24 h treatment with 1/2 MIC OX, the cytoplasmic consolidation of MRSA bacteriophage was not obvious. The cytoplasm was more uniform, and the cell wall grossness was seen to be damaged to different degrees (Figures 6(e) and 6(f)). After treatment with 1/2 MIC QXJT + OX for 24 h, it was observed that the MRSA bacteriophage was deformed, the cell wall was thin and discontinuous, the bacteriophage was severely damaged, and the cytoplasm was leaked. This indicated that QXJT + OX produced great damage to the cell wall of MRSA organisms, and this damage was more severe than that caused by either OX or QXJT alone. The synergistic nature of the cell wall damage was observed from the microscopic mechanism of the combination of the two (Figures 6(g) and 6(h)), and...
surprisingly, we observed that, after being treated by QXJT + OX, MRSA adhered together similar to “rose.” This is a unique form of disruption, and it is speculated that the combination of QXJT + OX may have influenced the division of MRSA organisms.

4.6. Quantitative Reverse-Transcription PCR. To further understand the interaction between QXJT and MRSA, the gene expression of superantigens was examined. The effect of different concentrations of QXJT, OX, and QXJT + OX on the transcription of sea, seb, tst, and meca of MRSA2007118 and MRSA2008043 genes was examined by fluorescence quantitative PCR technique, and the results are shown in Figure 7. There was no significant decrease in the transcription of sea, seb, and tst under the addition of 1/2 MIC QXJT, but the transcription of sea, seb, and tst was a statistically significant decrease under the addition of MIC QXJT compared with the control group. This inhibition showed a dose-dependent manner: the higher the dose, the stronger the inhibition. The transcriptions of sea, seb, and tst were also significantly decreased by 1/2 MIC, MIC OX, but the decrease was less than that of 1/2 MIC, MIC QXJT + OX, and the difference was statistically significant.

5. Discussion

Natural plants represent an almost unlimited (multitarget) source of active ingredients, and because of the wide variety, we usually rely on clinical or life experiences summarized by the ancients to screen drugs with possible antimicrobial effects for the extraction and study. QXJT is composed of different kinds and quantities of Chinese medicinal herbs with optimal therapeutic efficacy for a comprehensive regimen, according to the principles of traditional Chinese medicine (TCM). It may have more than one target and disturb bacterial physiology in several different pathways, which is beneficial for inflicting severe damage on the bacterial cell. The phenomenon is similar to polypharmacology [19, 20]. The antibacterial mechanism of QXJT is still unclear. We tried to reveal part of the mechanism by in vitro antibacterial experiment.

Due to the abuse of antibiotics and other factors, bacterial resistance has become more and more serious, which has become a century-old problem that needs to be solved in the future. Because of the high morbidity and mortality associated with MRSA, MRSA infection is considered one of the most challenging infectious diseases, resulting in a worse prognosis of sepsis and higher morbidity and mortality [21, 22]. Takesue et al. [23] demonstrated that the failure rate of vancomycin as first-line drug therapy against life-threatening MRSA disease is increasing. The successive reports of vancomycin heterogeneous resistant SA (hVRSA), vancomycin-mediated resistant SA (VISA), and vancomycin-resistant SA (VRSA) detected worldwide [24] remind us that we may be gradually losing the last line of defense against MRSA infection. The search for novel therapeutic agents that are effective against MRSA is therefore critical to maintaining public health in the future.

In our study, combining MIC and time-kill curve results, we found that QXJT showed significant bacterial inhibition against both clinical isolates of MRSA in a concentration-dependent manner. Active substances such as Scutellarein, Scutellarin, Apigenin, and Wogonin 7-O-glucuronide were...
detected in the phytochemical analysis that may be associated with the antimicrobial activity of QXJT. Perhaps this is because although the MRSA cell wall has a thick layer of peptidoglycan, this barrier is unable to block these tiny molecular compounds. These compounds on the cell wall of MRSA produced damage [25]. We also found that the MIC of MRSA2007118 to OX was about 4 mg/ml, which is four times higher than that of MRSA2008043, but MRSA2007118 was more sensitive to QXJT than MRSA2008043. MRSA is resistant to penicillin drugs by altering the structure of its cell wall through the mecA resistance gene [26]. But this resistance mutation did not show an advantage in resisting the damage caused by QXJT.

From the results of the checkerboard assay, we conclude that QXJT and OX have a significant synergistic effect (FICI = 0.5). We analyze the results of qPCR which show that QXJT and OX do not inhibit the mecA gene, so the synergistic mechanism of the two is not related to inhibiting the expression of drug resistance genes. By TEM images we observe that QXJT and OX are able to disrupt the cell wall, and QXJT + OX can produce greater damage to the cell wall. Through these results and our speculation that the effects of QXJT + OX combinations against MRSA may arise from two distinct types of mechanisms, the first of these is due to QXJT originally having a certain destructive effect on the bacterial cell wall, and this destructive effect can be subtly synergized with the destruction of the cell wall by OX, but the specific target of action is not clear; the second mechanism may arise from the ability of QXJT to inhibit the β-lactamase hydrolysis and restore MRSA sensitivity to OX.

Earlier studies focused more on the anti-inflammatory, antioxidant, and antibacterial effects of natural drugs [27–30]. Until recently, several researchers in diverse domains have expressed interest in strategies that target pathogen virulence factors [31]. It contradicts the antimicrobial effect of traditional antibiotics. Because virulence...
factors are not always required for bacterial survival, the antiviral method is under less pressure to target bacteria and is less vulnerable to bacterial resistance [13, 32].

Studies have shown that the protective effect of natural drugs such as baicalin against lethal infection with enterohemorrhagic Escherichia coli may be through direct interaction

### Table 3: QXJT and OX against MRSA.

| MIC strains       | QXJT (mg/mL) | OX (mg/mL) |
|-------------------|--------------|------------|
| MRSA2007118       | 18.75        | 4          |
| MRSA2008043       | 37.5         | 1          |

|                  | CIC          | FIC<sub>QXJT</sub> | FIC<sub>OX</sub> | FICI  |
|------------------|--------------|--------------------|------------------|------|
| QXJT + OX        | 4.69 mg/mLQXJT + 1 mg/mL OX | 0.25               | 0.25             | 0.5, synergism |
|                  | 9.38 mg/mLQXJT + 0.25 mg/mL OX | 0.25               | 0.25             | 0.5, synergism |

MIC, minimum inhibitory concentration; CIC, combined inhibitory concentration; FIC, fractional inhibitory concentration; FICI, fractional inhibitory concentration index.

### Figure 5: MRSA was incubated at different concentrations of QXJT from 1/4MIC to 4MIC. OD630 values were measured at 0, 2, 4, 8, 10, 12, and 24 h after treatment. Each experiment was repeated twice. (a) A time-kill assay of MRSA2007118. (b) A time-kill assay of MRSA2008043.

### Figure 6: (a, b) Transmission electron micrographs of untreated MRSA cells showing normal cell shapes. (c, d) Transmission electron micrographs of treated with 1/2 MIC of QXJT for 24 h. (e, f) Transmission electron micrographs of treated with 1/2 MIC of OX for 24 h. (g, h) Transmission electron micrographs of treated with 1/2 MIC of QXJT + OX for 24 h.
### Table

|                  | Control | 1/2QXJT | QXJT | 1/2OX | OX | 1/2QXJT+OX | QXJT+OX |
|------------------|---------|---------|------|-------|----|------------|---------|
| **sea** relative expression level | 1.5     | 1.2     | 0.8  | 0.6   | 1  | 0.8        | 0.6     |
| **seb** relative expression level | 3       | 2.5     | 2    | 1     | 1.5 | 1.2        | 1       |
| **tst** relative expression level  | 1.5     | 1.2     | 0.8  | 0.6   | 1  | 0.8        | 0.6     |

**Figure 7: Continued.**

- (a) Graph showing sea expression levels.
- (b) Graph showing sea expression levels.
- (c) Graph showing seb expression levels.
- (d) Graph showing seb expression levels.
- (e) Graph showing tst expression levels.
- (f) Graph showing tst expression levels.
Baicalin showed a significant inhibitory effect on the pathogenic factor hla of Staphylococcus aureus [34]. In our study, we found that QXJT + OX significantly inhibited the virulence factors such as sea, seb, and tst of MRSA in a concentration-dependent manner, and QXJT + OX could inhibit the virulence factors such as sea, seb, and tst more significantly. The exact mechanism remains unclear, but this regulatory role in virulence factors may provide new strategies for exploring new antibiotic drugs.

### 6. Conclusions

This article is based on a famous formula for treating sepsis caused by acute purulent infections of the face, hands, and feet: QXJT (a combination of natural drugs), created by Chen Shigong, a leading TCM surgeon with over 700 years of clinical application. In this study, QXJT showed good antimicrobial activity against a clinical isolate of MRSA. We found a significant synergistic effect of QXJT and OX in the combined form of traditional Chinese medicine and Western medicine, which may be related to the mechanism of action of QXJT to disrupt the cell wall of MRSA. However, its effect on the cell membrane cannot be excluded and still needs further study. We found that QXJT and QXJT in combination with OX could inhibit the expression of MRSA virulence factor but had no significant effect on MRSA resistance gene expression without significant effects, providing a new strategy for exploring new antibiotic drugs.

### Data Availability

Article data or supplementary data may be requested via e-mail to the author Siyuan Lv (lvsiyuan2008@126.com) and will be shared with applicants.

### Conflicts of Interest

The authors declare no conflicts of interest.

### Acknowledgments

The authors are thankful for the funding of National Natural Science Project (8157150997). The work was supported by Dongzhimen Hospital, Beijing University of Chinese Medicine.
References

[1] E. Salmerón-Manzano, J. A. Garrido-Cardenas, and F. Manzano-Aguilario, "Worldwide research trends on medicinal plants," *International Journal of Environmental Research and Public Health*, vol. 17, no. 10, Article ID 3376, 2020.

[2] M. Miethke, M. Pieroni, T. Weber, M. Brnstrup, and R. Müller, "Towards the sustainable discovery and development of new antibiotics," *Nature Reviews Chemistry*, vol. 5, no. 10, pp. 1–24, 2021.

[3] G. Porras, F. Chassagne, J. T. Lyles et al., "Ethnobotany and the role of plant natural products in antibiotic drug discovery," *Chemical Reviews*, vol. 121, no. 6, pp. 3495–3560, 2021.

[4] W. Zhou, X. Cheng, and Y. Zhang, "Effect of Liuwei Dihuang decoction, a traditional Chinese medicinal prescription, on the neuroendocrine immunomodulation network," *Pharmacology & Therapeutics*, vol. 162, no. 4, pp. 170–178, 2016.

[5] H. Chen and S. Wang, "Treatment of 100 cases of acute sore with Qixingqian decoction," *Journal of Nanjing University of Traditional Chinese Medicine*, no. 4, pp. 250–251, 1992.

[6] G. Lin, Y. Zhu, and X. Wu, "Clinical summary of the treatment of 339 cases of facial skullcap with Qixingqian decoction," *Jiangsu Journal of Traditional Chinese Medicine*, vol. 32, no. 8, pp. 24–25, 1987.

[7] F. D. Lowy, "*Staphylococcus aureus* infections," *New England Journal of Medicine*, vol. 339, no. 8, pp. 520–532, 1998.

[8] S. J. van Hal, S. O. Jensen, V. L. Vaska, B. A. Espedido, D. L. Paterson, and I. G. Gossell, "Predictors of mortality in *Staphylococcus aureus* bacteremia," *Clinical Microbiology Reviews*, vol. 25, no. 2, pp. 362–386, 2012.

[9] M. P. Jevons, ""Celbenin"—resistant *Staphylococcus*," *BMJ Clinical Research*, vol. 1, no. 5219, 1961.

[10] M. W. Ellis, D. R. Hospenthal, D. P. Dooley, P. J. Gray, and C. K. Murray, "Natural history of community-acquired methicillin-resistant *Staphylococcus aureus* colonization and infection in soldiers," *Clinical Infectious Diseases*, vol. 39, no. 7, pp. 971–979, 2004.

[11] I. X. Liu, D. G. Durham, and R. M. E. Richards, "Baicalin synergy with β-lactam antibiotics against methicillin-resistant *Staphylococcus aureus* and other β-lactam-resistant strains of *S. aureus*," *Journal of Pharmacy and Pharmacology*, vol. 52, no. 3, pp. 361–366, 2010.

[12] R. R. Watkins, M. Z. David, and R. A. Salata, "Current concepts on the virulence mechanisms of meticillin-resistant *Staphylococcus aureus*," *Journal of Medical Microbiology*, vol. 61, no. 9, pp. 1179–1193, 2012.

[13] C. Kong, H. Neoh, and S. Nathan, "Targeting *Staphylococcus aureus* toxins: a potential form of anti-virulence therapy," *Toxins*, vol. 8, no. 3, p. 72, 2016.

[14] F. Ceriotti, J. Žakowski, H. Sine, S. Altaie, G. Horowitz, and A. J. Pesce Clinical and Laboratory Standards Institute (CLSI), 2012.

[15] H. Xu, C. Liu, M. Li et al., "In vitro antibacterial experiment of Fuzheng Jiedu Huayu decoction against multidrug-resistant *Pseudomonas aeruginosa*," *Frontiers in Pharmacology*, vol. 10, Article ID 1682, 2019.

[16] A. López-Malo, E. Palou, M. E. Parish, and P. M. Davidson, "Methods for activity assay and evaluation of results," *Antimicrobials in Food*, CRC Press, Boca Raton, FL, USA, 2005.

[17] Z. Schelz, J. Molnar, and J. Hohmann, "Antimicrobial and antiplasmid activities of essential oils," *Fitoterapia*, vol. 77, no. 4, pp. 279–285, 2006.

[18] H.-N. Li, C.-Y. Wang, C.-L. Wang, C.-H. Chou, Y.-L. Leu, and B.-Y. Chen, "Antimicrobial effects and mechanisms of ethanol extracts of Psoralea corylifolia seeds against Listeria monocytogenes and methicillin-resistant *Staphylococcus aureus*," *Foodborne Pathogens and Disease*, vol. 16, no. 8, pp. 573–580, 2019.

[19] A. S. Reddy and S. Zhang, "Polypharmacology: drug discovery for the future," *Expert Review of Clinical Pharmacology*, vol. 6, no. 1, pp. 41–47, 2013.

[20] X. Wei, Y. Wang, Y. Bai, and W. Zhang, "Polypharmacology in drug discovery: a review from systems pharmacology perspective," *Current Pharmaceutical Design*, vol. 22, no. 21, pp. 3171–3181, 2016.

[21] M. Z. David and R. S. Daum, "Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic," *Clinical Microbiology Reviews*, vol. 23, no. 3, pp. 616–687, 2010.

[22] I. P. Thomsen, "The concern for vancomycin failure in the treatment of pediatric *Staphylococcus aureus* disease," *Clinical Infectious Diseases*, vol. 68, no. 3, pp. 373–374, 2019.

[23] Y. Takesue, K. Nakajima, Y. Takahashi et al., "Clinical characteristics of vancomycin minimum inhibitory concentration of 2μg/ml methicillin-resistant *Staphylococcus aureus* strains isolated from patients with bacteremia," *Journal of Infection and Chemotherapy*, vol. 17, no. 1, pp. 52–57, 2011.

[24] J. W. Park, H. Lee, J. W. Kim, and B. Kim, "Characterization of infections with vancomycin-intermediate *Staphylococcus aureus* (VISA) and *Staphylococcus aureus* with reduced vancomycin susceptibility in South Korea," *Scientific Reports*, vol. 9, no. 1, Article ID 6236, 2019.

[25] A. D. Russell, "Bacterial resistance to disinfectants: present knowledge and future problems," *Journal of Hospital Infection*, vol. 43, pp. S57–S68, 1999.

[26] C. Fuda, J. Fisher, and S. Mobashery, "β-lactam resistance in *Staphylococcus aureus*: the adaptive resistance of a plastic genome," *Cellular and Molecular Life Sciences*, vol. 62, no. 22, pp. 2617–2633, 2005.

[27] A. Aimad, R. Sanae, F. Anas et al., "Chemical characterization and antioxidant, antimicrobial, and insecticidal properties of essential oil from *Mentha pulegium L.*," *Evidence-based Complementary and Alternative Medicine*, 2021, Article ID 1108133, 12 pages, 2021.

[28] M. Rodrigues, A. C. Lopes, F. Vaz et al., "Thymus mastichina: composition and biological properties with a focus on antimicrobial activity," *Pharmaceutica*, vol. 13, no. 12, p. 479, 2020.

[29] I. Bassolé and H. Juliani, "Essential oils in combination and their antimicrobial properties," *Molecules*, vol. 17, no. 4, pp. 3989–4006, 2012.

[30] N. Martins, L. Barros, C. Santos-Buelga, S. Silva, M. Henriques, and I. C. F. R. Ferreira, "Decoction, infusion and hydroalcoholic extract of cultivated thyme: antioxidant and antimicrobial activities, and phenolic characterisation," *Food Chemistry*, vol. 167, pp. 131–137, 2015.

[31] R. A. Brady, C. P. Mocca, R. Prabhakara et al., "Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of *Staphylococcus aureus* infection," *PLoS One*, vol. 8, no. 4, Article ID e63040, 2013.

[32] B. Park and G. Y. Liu, "Targeting the host-pathogen interface for treatment of *Staphylococcus aureus* infection," *Seminars in Immunopathology*, vol. 34, no. 2, pp. 299–315, 2012.
[33] Y. Zhang, Z. Qi, Y. Liu et al., “Baicalin protects mice from lethal infection by enterohemorrhagic Escherichia coli,” *Frontiers in Microbiology*, vol. 8, p. 395, 2017.

[34] S. Zhang, B. Hu, J. Xu et al., “Baicalin suppress growth and virulence-related factors of methicillin-resistant Staphylococcus aureus in vitro and vivo,” *Microbial Pathogenesis*, vol. 139, Article ID 103899, 2020.